An antigenic determinant capable of inducing type-common herpes simplex virus (HSV)-neutralizing antibodies has been located on glycoprotein D (gD) of HSV type 1 (HSV-1). A peptide of 16 amino acids corresponding to residues 8 to 23 of the mature glycoprotein (residues 33 to 48 of the predicted gD-1 sequence) was synthesized. This peptide reacted with an anti-gD monoclonal antibody (group VII) previously shown to neutralize the infectivity of HSV-1 and HSV-2. The peptide was also recognized by polyclonal antibodies prepared against purified gD-1 but was less reactive with anti-gD-2 sera. Sera from animals immunized with the synthetic peptide reacted with native gD and neutralized both HSV-1 and HSV-2.
recognized by group VII antibodies made it feasible to consider the synthesis of a peptide that might stimulate production of type-common neutralizing antibody. Such a synthetic peptide might have potential as a vaccine (1) .
For this report, peptides were synthesized corresponding to the most probable amino acid sequence of the group VII determinant of gD. Analysis of these peptides with antibodies directed against gD-1 and gD-2 indicated that the group VII epitope was contained within one of these peptides (16-mer) . This peptide was coupled to protein carriers and was used to immunize rabbits and mice. Anti-16-mer sera reacted with the synthetic peptides and with native gD and neutralized HSV in a type-common fashion.
MATERIALS AND METHODS Cells and virus. Conditions for the growth and maintenance of BHK and KB cells and the propagation of virus have been described previously (7) . For infection, an input multiplicity of 20 PFU of HSV-1 (strain HF) and 10 PFU of HSV-2 (strain SAVAGE) per cell was used.
Labeling procedures. HSV-1-and HSV-2-infected cells were labeled by the methods described previously (6, 12, 13) . Monolayers (75-cm2 flask) were pulse-labeled for 15 min at 6 h postinfection in Hanks salts with [35S]methionine (specific activity, 600 Ci/mmol, 750 ,uCi), and cytoplasmic extracts were prepared (6, 12, 13) . Purification of gD from HSV-1-infected KB cells and HSV-2-infected BHK cells was carried out as previously described (13) . The isotope was purchased from New England Nuclear Corp.
Preparation of antisera and monoclonal antibodies. AntigD-1 and anti-gD-2 sera were prepared in rabbits and mice against purified preparations of gD-1 and gD-2 (6, 13) . Preparation of group VII monoclonal antibodies (represented by antibody 170) with strain G of HSV-2 was previously described (12, 24) . Antisera to the synthetic peptides were prepared as follows. BALB/c mice were immunized four times at biweekly intervals by intraperitoneal injection of Long, and R. J. Eisenberg, unpublished data). These data suggested that the f peptide consisted of residues 36 to 41 of the deduced amino acid sequence of gD-1 (30) . Together, these data suggested that the group VII determinant was near the amino terminus of gD-1. Figure 1 shows a computer representation of the secondary structure of gD-1, by the use of the predicted amino acid sequence of Watson et al. (30) and rules established by Chou and Fasman (8, 9) . For these calculations, we excluded the first 25 amino acids of the predicted sequence (30) from consideration, since direct N-terminal sequence analysis showed that lysine residue 26 of the deduced sequence was the amino terminus of mature gD-1 (lla). By the use of stringent criteria (probability of a turn [Pt] . 7.5 x 10-5), 17 ,B-turns are predicted for this sequence. Also shown in Fig. 1 is a second empirical analysis which assumes that hydrophilic regions of protein structures have a greater immunological potential (15) . The predictive value of this method for positioning the group VII determinant is partly based on the assumption that the epitope is continuous in nature (2) . The two types of analyses show that the first 13-turn in the Nterminal region of the molecule overlaps with a highly hydrophilic region (open circles) and therefore is a likely candidate for an antigenic site. The sequence of the 23 amino acids encompassing this turn is shown in the insert (Fig. 1 ) and includes the f peptide (met-ala-asp-pro-asn-arg).
Recognition of the synthetic peptide by group VII monoclonal antibody and by polyclonal anti-gD-sera. To test the prediction that the group VII epitope was in the first 13-turn, we synthesized the series of peptides shown in Fig. 2 .
Cysteine was added to the carboxy terminus of each peptide to facilitate coupling to a protein carrier. Polyclonal antiserum prepared to purified gD-2 (rabbit 3) did not react with the 16-mer (lane F, row 4), and serum from another gD-2 immunized animal (rabbit 4) showed only slight reactivity with this peptide (lane F, row 5). Similarly, pooled mouse sera prepared against purified gD-2 did not react with the 16-mer (data not shown). The pooled mouse anti-gD-1 serum (lane F, row 6), however, did react with the 16-mer. These results suggest that the antigenic determinant of gD-1 which is present in the 16-mer is different from the corresponding determinant in gD-2.
Specificity of the reaction between monoclonal antibody and the 16-mer peptide. Representatives of six of the eight groups of monoclonal antibodies to gD (12) were tested in the dotblot assay against gD-1, gD-2, and the 16-mer (Fig. 4) . Each antibody (rows 1 to 6) reacted with either gD-1 (lane B), gD-2 (lane C), or both. However, only group VII antibody 170 reacted with the 16-mer (lane D, row 2), thus demonstrating the specificity of the reaction.
Immune response to the 16-mer. (i) Dot-blot assay. Antisera were prepared in both mice and rabbits to the 16-mer peptide covalently bound to KLH or OVA. The reactivity of these sera with gD-1 and gD-2, as well as with the 7-, 11-, and 16-mer peptides, is shown in Fig. 5 N-asp-pro-asn-arg-pho-arg-g ly-lys-asp-lou-pro-cyG 7mor N-pho-arg-gly-lys-asp-lou-pro-cys FIG. 2. Amino acid sequence of the synthetic peptides that overlap the first 1-turn of gD-1. Three peptides were synthesized, and in each case, cysteine was added to the carboxy terminus to facilitate coupling to a protein carrier. The numbers in parentheses refer to the residue numbers of the predicted sequence of gD-1 (30 E) .
(ii) Radioimmunoprecipitation of gD by antisera prepared against the 16-mer. Figure 6 shows the electrophoretic pattern of radioactive proteins which were immunoprecipitated from cytoplasmic extracts of HSV-1-or HSV-2-infect-A B C D The antibodies used (grouped as described in reference 12) were as follows: row 1, group I, HD-1: row 2, group VII, 170; row 3, group V, 57S: row 4. group IV, 1S: row 5, group III, 11S; row 6, group VI. 45S: row 7, pooled sera from sham-immunized mice; row 8, anti-gD-1 (rabbit 1): row 9, anti-gD-2 (rabbit 3); rows 10 and 11, preimmune rabbit serum. The strips in rows 1 to 7 were exposed to X-ray film for 7 days; rows 8 to 10 were exposed for Control reactions with polyclonal anti-gD-1 and anti-gD-2 sera (Fig. 6A. lanes 1 and 2 and Fig. 6B, lane 1) show the positions of the precursors pgD-1 and pgD-2 (6). Each serum prepared against the 16-mer (Table 1) was tested against these cell extracts in a similar fashion. Mouse anti-16-mer-KLH serum reacted with pgD-1 (Fig. 6A, lane 4) and pgD-2 (Fig. 6B, lane 3) . None of the other mouse (Fig. 6A, lanes 5  and 6 and Fig. 6B, lanes 4 and 5) or rabbit sera prepared against the 16-mer immunoprecipitated pgD (data not shown for rabbit sera).
(iii) Virus neutralization. Previously we showed that antisera prepared against purified gD-1 or gD-2 neutralized both HSV-1 and HSV-2 (6, 13) . In addition, group VII monoclonal antibody exhibited low titers of type-common neutralizing activity (12, 24) . Each serum prepared against the 16-Wer was tested for virus neutralization ( Table 1) . As controls, each of the polyclonal sera and antibody 170 was titered in the same assay. Rabbit sera prepared against the 16-mer OVA and the 16-mer KLH and mouse anti-16-mer-KLH serum neutralized both HSV-1 and HSV-2. The titers were comparable to those obtained with antibody 170. When serum from rabbit 7 (anti-16-mer OVA) was depleted of complement by heat inactivation, the titers were significantly lower. In contrast, inactivation of complement had little or no effect on the titers of hyperimmune anti-gD sera, mouse anti-16-mer-KLH serum, or antibody 170. philic regions (15) suggested that the determinant was in the first n-turn near the amino terminus of gD-1. We were able to localize this determinant between residues 8 and 23 of gD-1, based on the specificity of group VII monoclonal antibody 170 for the 16-mer peptide.
The reactivity of anti-gD-1 sera with the 7-mer, 11-mer, and 16-mer suggests the existence of several epitopes in the N-terminal region of gD-1. In contrast, the almost complete lack of reactivity of anti-gD-2 sera with any of the peptides suggests that gD-2 is structurally different in this region from gD-1. The amino acid sequences of gD-1 and gD-2 appear to be quite similar at the amino terminus (lla). However, it is possible that a difference in even one amino acid could impose drastic changes in structure and antigenicity. Knowledge of the full sequence of gD-2 should help to explain the observed differences.
In this study, we assessed the immunogenicity of the 16-mer by injecting mice and rabbits with preparations of this peptide either uncoupled or coupled to two different carriers, KLH and OVA. We observed that the coupled 16 -mer induced a diverse antibody response. The antisera recognized the synthetic peptides, as well as gD-1 and gD-2. Of interest was the finding that at least some of these antisera neutralized HSV-1 and HSV-2. In one case, the titer appeared to be partly complement dependent, whereas the neutralizing activity of monoclonal antibody 170 appears to be largely independent of complement. This may be a reflection of the diversity of antibodies raised to the synthetic peptide. It was also noted that the neutralization titers of the anti-peptide sera were considerably lower than those of the anti-gD sera but were comparable to that of antibody 170. We showed previously that several groups of gD monoclonal antibodies exhibit high titers of neutralizing activity (12) . Thus, the high neutralizing activity of polyclonal anti-gD serum represents a composite of antibodies to several determinants, of which the group VII determinant is only one. Future experiments will assess the protective effect induced by immunization with the synthetic peptide. For foot-and-mouth disease virus, a synthetic peptide corresponding to a portion of VP1 capsid protein stimulated production of neutralizing antibody and protected guinea pigs against subsequent virus challenge (4). A similar philosophy has been utilized in manufacturing potential synthetic peptide vaccines for a number of viruses (reviewed in reference 19). Though it is possible that the production of neutralizing antibody may not be a prerequisite for protection against HSV infection, the synthetic peptide nevertheless does stimulate an immune response to gD which includes virus neutralization and thus has potential practical application.
